Chinese biotechnology start-up AnHeart Therapeutics announced on Wednesday that it has raised approximately RMB100 million (US$14.54 million) in a series A round of financing from the country’s venture capital firm Decheng Capital.

UNLOCK DATASubscribe & Access the Best Data and Intelligence on Chinese Venture Capital and Tech